Redhill Biopharma

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on gastrointestinal diseases and infectious diseases. RedHill promotes the following gastrointestinal drugs: Movantik® for the treatment of opioid-induced constipation in adults, Talicia® for the treatment of Helicobacter pylori (H. pylori) infection in adults, and Aemcolo® for the treatment of traveler's diarrhea in adults. Key late-stage clinical development programs of RedHill include: (i) RHB-204, with a planned Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease infections; (ii) opaganib (ABC294640), a first-in-class oral SK2 selective inhibitor for multiple indications, with a Phase 2/3 oral drug program for COVID-19 and a Phase 2 study for prostate cancer and cholangiocarcinoma; (iii) RHB-107 (upamostat), an oral serine protease inhibitor currently in a Phase 2/3 study in the United States for symptomatic COVID-19, targeting various other cancers and inflammatory gastrointestinal diseases; (iv) RHB-104, which achieved positive results in its first Phase 3 study for Crohn's disease; (v) RHB-102, which achieved positive results in a Phase 3 study for acute gastroenteritis and gastritis and in a Phase 2 study for IBS-D; (vi) RHB-106, an encapsulated bowel preparation.